Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NAMS stock hub

NewAmsterdam Pharma Company N.V. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NAMSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NAMS

In the news

Latest news · NAMS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-29.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-18.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NAMS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001936258
Company name	NewAmsterdam Pharma Company N.V.
Country	Netherlands
Country code	US
Employees	100
Employees Change	32%
Employees Change Percent	47.06
Enterprise value	$3.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	NL00150012L7
Last refreshed	2026-05-10
Market cap	$4.5B
Market cap category	Mid-Cap
Price	$38.73
Price currency	USD
Rev Per Employee	225,650x
Sector	Healthcare
Sic	2834
Symbol	NAMS
Website	https://www.newamsterdampharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-4.78%
EV Sales Forward	136.82x
EV/Sales	166x
FCF yield	-3.19%
P/B ratio	6.79x
P/S ratio	197.34x
PS Forward	162.66x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$22.6M
Gross Profit Growth	-52.13%
Gross Profit Growth Q	2.08%
Gross Profit Growth3 Y	-28.03%
Net Income	$-212.7M
Net Income Growth Years	1%
Pretax Margin	-942.76%
Profit Per Employee	$-2.1M
ROA	-17.34
Roa5y	-23.93
ROCE	-32.35
ROE	-29.49
Roe5y	-58.41
ROIC	-18.64

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	104.8%
Cagr3y	40.81%
Cagr5y	31.37%
EPS Growth Years	1
Revenue Growth	-52.13x
Revenue Growth Q	2.08x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-28.03x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$732.6M
Cash	$636.1M
Current Assets	$658M
Current Liabilities	$67.4M
Debt	$23,000
Debt Equity	$0
Equity	$665.2M
Liabilities	$67.4M
Long Term Assets	$74.6M
Long Term Liabilities	$0
Net Cash	$707.3M
Net Cash By Market Cap	$15.88
Net Cash Growth	-12.47%
Net Debt Equity	$-1.06
Tangible Book Value	$664.8M
Tangible Book Value Per Share	$5.7
WACC	4.41

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.76
Net Working Capital	$-45.5M
Quick ratio	9.43
Working Capital	$590.6M
Working Capital Turnover	$0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-18.07%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	104.7%
200-day SMA	31.95
3Y total return	179.24%
50-day SMA	31.66
50-day SMA vs 200-day SMA	50under200
5Y total return	291.21%
All Time High	42
All Time High Change	-7.79%
All Time High Date	2025-11-26
All Time Low	5.63
All Time Low Change	587.56%
All Time Low Date	2023-10-26
ATR	2.2
Beta	0.03
Beta1y	1.09
Beta2y	1.13
Ch YTD	10.41
High	41.17
High52	42
High52 Date	2025-11-26
High52ch	-7.79%
Low	34.85
Low52	16.79
Low52 Date	2025-05-28
Low52ch	130.74%
Ma50ch	22.32%
Premarket Change Percent	0.11
Premarket Price	$34.89
Premarket Volume	18,738
Price vs 200-day SMA	21.24%
RSI	70.64
RSI Monthly	63.84
RSI Weekly	59.64
Sharpe ratio	1.47x
Sortino ratio	2.47
Total Return	-18.07%
Tr YTD	10.41
Tr1m	14.21%
Tr1w	36.23%
Tr3m	12.92%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	3
Analyst Price Target Top	$47.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.43
Earnings Revenue Estimate	1,190,416x
Earnings Revenue Estimate Growth	-60.03x
Operating Income	$-215.2M
Operating margin	-953.6
Price target	$46.75
Price Target Change	$20.71
Price Target Change Top	$23.08

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	71,466,056%
Float Percent	62.16%
Shares Insiders	0.35%
Shares Institutions	70.23%
Shares Out	114,975,422
Shares Qo Q	0.93%
Shares Yo Y	18.07%
Short Ratio	8.86
Short Shares	7.94

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-204.4M
Average Volume	1,251,151.4x
Bv Per Share	5.7
CAPEX	$-268,000
Ch1m	14.21
Ch1w	36.23
Ch1y	104.7
Ch3m	12.92
Ch3y	179.2
Ch5y	291.2
Ch6m	5.36
Change	11.13%
Change From Open	11.13
Close	34.85
Days Gap	0
Depreciation Amortization	230,000
Dollar Volume	186,131,654.9
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-215.2M
EBITDA	$-214.9M
EPS	$-1.78
F Score	1
FCF	$-142.2M
FCF EV Yield	-3.8x
FCF Per Share	$-1.24
Financing CF	34,066,000
Fiscal Year End	December
Founded	2,019
Investing CF	-189,280,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-18
Ma150	34.23
Ma150ch	13.15%
Ma20	32.04
Ma20ch	20.87%
Net CF	-289,477,000
Next Earnings Date	2026-08-05
Open	34.85
Optionable	Yes
Position In Range	61.39
Ppne	400,000
Pre Close	34.85
Price Date	2026-05-08
Ptbv Ratio	6.7
Relative Volume	3.84x
Revenue	22,565,000x
SBC By Revenue	275.71x
Share Based Comp	62,214,000
Tr6m	5.36%
Volume	4,805,878

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NAMS pay a dividend?

Capital-return profile for this ticker.

Performance

NAMS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NAMS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+70.2%

Float: +62.2% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NAMS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.6

Above 70: short-term overbought

Price vs 200-day MA

+21.2%

50/200-day relationship not available

Beta (5Y)

0.03

Less volatile than the market

Sharpe ratio

1.47

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NAMS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NAMS stock rating?

NewAmsterdam Pharma Company N.V. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NAMS analysis?

The full report lives at /stocks/NAMS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NAMS?

The latest report frames NAMS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NAMS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.